Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well M1774 works in treating patients with prostate cancer that
does not respond to treatment (refractory) and who have a mutation in the speckle type
BTB/POZ protein (SPOP) gene. M1774 may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.